Pett, S. L., Amin, J., Horban, A., Andrade-Villanueva, J., Losso, M., Porteiro, N., . . . Emery, S. (2018). Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study. HIV Medicine, 19 (1), 65-71. doi:10.1111/hiv.12532

Hakim, J. G., Musiime, V., Szubert, A., Mallewa, J., Siika, A., Agutu, C., . . . Gibb, D. M. (2017). Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. New England Journal of Medicine. doi:10.1056/NEJMoa1615822

Pett, S. L., Amin, J., Horban, A., Andrade-Villanueva, J., Losso, M., Porteiro, N., . . . Emery, S. (2016). Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 63 (1), 122-132.

Amin, J., Becker, S., Belloso, W., To, M. B., Cooper, D., Crabtree-Ramirez, B., . . . Dolan, M. (2015). Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. LANCET INFECTIOUS DISEASES, 15 (7), 793-802. doi:10.1016/S1473-3099(15)70060-5

Borges, A. H., O'Connor, J. L., Phillips, A. N., Ronsholt, F. F., Pett, S., Vjecha, M. J., . . . Lundgren, J. D. (2015). Factors Associated With Plasma IL-6 Levels During HIV Infection. JOURNAL OF INFECTIOUS DISEASES, 212 (4), 585-595. doi:10.1093/infdis/jiv123

Flower, B., Hung, L. M., Mccabe, L., Ansari, M. A., Le Ngoc, C., Vo Thi, T., . . . Cooke, G. S. (2023). Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for Hepatitis C: a single arm mechanistic pilot study. eLife. doi:10.7554/elife.81801

Maalej, N. H., Collins, I. J., Ades, A. E., Scott, K., Judd, A., Mostafa, A., . . . Deuffic-Burban, S. (2023). Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine. Journal of Hepatology. doi:10.1016/j.jhep.2022.12.032

Sy, A., McCabe, L., Hudson, E., Ansari, A., Pedergnana, V., Lin, S. -. K., . . . Cooke, G. (2023). Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus. PLoS One.

ACTIV-3/TICO Study Group*. (2022). Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial. Ann Intern Med. doi:10.7326/M22-1503

Self, W. H., Sandkovsky, U., Reilly, C. S., Vock, D. M., Gottlieb, R. L., Mack, M., . . . Lundgren, J. D. (2022). Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infectious Diseases, 22 (5), 622-635. doi:10.1016/S1473-3099(21)00751-9